Spyre Therapeutics, Inc. SYRE Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s total assets?
- Spyre Therapeutics, Inc. (SYRE) reported total assets of $763.95M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total assets changed year-over-year?
- Spyre Therapeutics, Inc.'s total assets increased by 34.1% year-over-year, from $569.78M to $763.95M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total assets?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total assets has grown at a 36.9% compound annual growth rate (CAGR), from $161.62M to $777.78M.
- What does total assets mean?
- The total value of everything the company owns.
- How do you interpret total assets?
- Growth in total assets generally reflects capital accumulation for R&D, whereas a decline may indicate asset depletion or impairment.
- How does total assets compare across companies?
- Used to benchmark the size and capital intensity of biotech firms at similar stages of clinical development.